Position in JANX
as of Jun 30, 2026
· filed Jul 8, 2026
Position Value
$473,856
+$46,987 QoQ
Shares Held
30,850
+0.5% QoQ
Ownership
0.051%
of shares outstanding
% of Portfolio
0.20%
of 13F equity value
Holder Rank
#2
of 4 holders
Holding Since
Jun 2024
9 quarters on record
Voting authority
Sole 100.ToString("F0")%
Shared 0.ToString("F0")%
None 0.ToString("F0")%
Common Shares in JANX Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026FNY Investment Advisers, LLC holds $19,945,542 across 57 Biotechnology names. JANX ranks #5 (2.4% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | NUVL |
Nuvalent, Inc.
|
108,951 | $13,455,448 | |
| 2 | ABVX |
Abivax S.A.
|
7,605 | $1,013,442 | |
| 3 | SGMT |
Sagimet Biosciences Inc.
|
109,250 | $844,502 | |
| 4 | APGE |
Apogee Therapeutics, Inc.
|
5,000 | $663,650 | |
| 5 | JANX |
Janux Therapeutics, Inc.
This page
|
30,850 | $473,856 | |
| 6 | NKTR |
Nektar Therapeutics
|
5,500 | $383,955 | |
| 7 | VERU |
Veru Inc.
|
105,081 | $328,903 | |
| 8 | VKTX |
Viking Therapeutics, Inc.
|
8,170 | $318,711 |
All Filings in JANX
Export CSV
9 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $473,856 | 30,850 | Shares | Sole | 2026-07-08 | |
| 2026-03-31 | $426,869 | 30,710 | Shares | Sole | 2026-04-15 | |
| 2025-12-31 | $142,140 | 10,300 | Shares | Sole | 2026-01-16 | |
| 2025-09-30 | $127,332 | 5,210 | Shares | Sole | 2025-12-15 | |
| 2025-06-30 | $120,351 | 5,210 | Shares | Sole | 2025-07-30 | |
| 2025-03-31 | $66,420 | 2,460 | Shares | Sole | 2025-04-17 | |
| 2024-12-31 | $1,873 | 35 | Shares | Sole | 2025-01-13 | |
| 2024-09-30 | $27,258 | 600 | Shares | Sole | 2024-10-18 | |
| 2024-06-30 | $27,228 | 650 | Shares | Sole | 2024-08-05 | |
| No filing history on record for this holder in this stock. | ||||||